Clinical Trial Update: Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the imaging agent 68Ga-FAP-2286 for pathologic fibrosis in liver, lung, and heart has completed its Phase 1 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Myocardial Fibrosis
• Pulmonary Fibrosis

Drugs mentioned

• 68Ga-FAP-2286

Snippet

Sponsor: Thomas Hope | Conditions: Liver Fibrosis, Pulmonary Fibrosis | Phase 1 | Status: COMPLETED